

# Bruce R Schackman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2937151/publications.pdf>

Version: 2024-02-01

185  
papers

7,747  
citations

61857

43  
h-index

60497

81  
g-index

189  
all docs

189  
docs citations

189  
times ranked

7783  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Survival Benefits of AIDS Treatment in the United States. <i>Journal of Infectious Diseases</i> , 2006, 194, 11-19.	1.9	576
2	Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 Infection. <i>New England Journal of Medicine</i> , 2004, 350, 1850-1861.	13.9	495
3	The Lifetime Cost of Current Human Immunodeficiency Virus Care in the United States. <i>Medical Care</i> , 2006, 44, 990-997.	1.1	388
4	Prescription Drug Monitoring Programs Are Associated With Sustained Reductions In Opioid Prescribing By Physicians. <i>Health Affairs</i> , 2016, 35, 1045-1051.	2.5	273
5	HIV Preexposure Prophylaxis in the United States: Impact on Lifetime Infection Risk, Clinical Outcomes, and Cost-Effectiveness. <i>Clinical Infectious Diseases</i> , 2009, 48, 806-815.	2.9	240
6	Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. <i>Journal of Substance Abuse Treatment</i> , 2018, 85, 90-96.	1.5	233
7	Three- vs Four-Drug Antiretroviral Regimens for the Initial Treatment of HIV-1 Infection <SUBTITLE>A Randomized Controlled Trial</SUBTITLE>. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 769.	3.8	209
8	Expanded HIV Screening in the United States: Effect on Clinical Outcomes, HIV Transmission, and Costs. <i>Annals of Internal Medicine</i> , 2006, 145, 797.	2.0	183
9	Preexisting Resistance to Nonnucleoside Reverse-Transcriptase Inhibitors Predicts Virologic Failure of an Efavirenz-Based Regimen in Treatment-Naive HIV-1-Infected Subjects. <i>Journal of Infectious Diseases</i> , 2008, 197, 867-870.	1.9	170
10	Racial and Sex Disparities in Life Expectancy Losses among HIV-Infected Persons in the United States: Impact of Risk Behavior, Late Initiation, and Early Discontinuation of Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2009, 49, 1570-1578.	2.9	167
11	Preexisting Minority Drug-Resistant HIV-1 Variants, Adherence, and Risk of Antiretroviral Treatment Failure. <i>Journal of Infectious Diseases</i> , 2010, 201, 100126095936095-000.	1.9	155
12	The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. <i>Aids</i> , 2008, 22, 2025-2033.	1.0	130
13	The Quality of Highly Regarded Adolescent Substance Abuse Treatment Programs. <i>JAMA Pediatrics</i> , 2004, 158, 904.	3.6	117
14	Economic Savings Versus Health Losses: The Cost-Effectiveness of Generic Antiretroviral Therapy in the United States. <i>Annals of Internal Medicine</i> , 2013, 158, 84.	2.0	117
15	Variation in Orthopaedic Surgeons' Perceptions About the Indications for Rotator Cuff Surgery. <i>Journal of Bone and Joint Surgery - Series A</i> , 2005, 87, 1978-1984.	1.4	114
16	A Call For Evidence-Based Medical Treatment Of Opioid Dependence In The United States And Canada. <i>Health Affairs</i> , 2013, 32, 1462-1469.	2.5	114
17	Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort. <i>Drug and Alcohol Dependence</i> , 2019, 200, 34-39.	1.6	113
18	Effect of Risk-Reduction Counseling With Rapid HIV Testing on Risk of Acquiring Sexually Transmitted Infections. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 1701.	3.8	111

#	ARTICLE	IF	CITATIONS
19	The Hepatitis C Cascade of Care: Identifying Priorities to Improve Clinical Outcomes. PLoS ONE, 2014, 9, e97317.	1.1	109
20	States With Prescription Drug Monitoring Mandates Saw A Reduction In Opioids Prescribed To Medicaid Enrollees. Health Affairs, 2017, 36, 733-741.	2.5	102
21	Comparison of Health State Utilities Using Community and Patient Preference Weights Derived from a Survey of Patients with HIV/AIDS. Medical Decision Making, 2002, 22, 27-38.	1.2	100
22	The Lifetime Medical Cost Savings From Preventing HIV in the United States. Medical Care, 2015, 53, 293-301.	1.1	94
23	The Cost-Effectiveness of Sofosbuvir-Based Regimens for Treatment of Hepatitis C Virus Genotype 2 or 3 Infection. Annals of Internal Medicine, 2015, 162, 619-629.	2.0	92
24	Implementing Rapid HIV Testing With or Without Risk-Reduction Counseling in Drug Treatment Centers: Results of a Randomized Trial. American Journal of Public Health, 2012, 102, 1160-1167.	1.5	86
25	Cost-Effectiveness of Long-Term Outpatient Buprenorphine-Naloxone Treatment for Opioid Dependence in Primary Care. Journal of General Internal Medicine, 2012, 27, 669-676.	1.3	81
26	Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer. Cancer, 2009, 115, 3858-3867.	2.0	78
27	Newer drugs and earlier treatment. Aids, 2012, 26, 45-56.	1.0	74
28	Implementation Science for the Prevention and Treatment of HIV/AIDS. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, S27-S31.	0.9	71
29	Appropriateness Criteria and Elective Procedures – Total Joint Arthroplasty. New England Journal of Medicine, 2012, 367, 2467-2469.	13.9	70
30	Inappropriate Medication in a National Sample of US Elderly Patients Receiving Home Health Care. Journal of General Internal Medicine, 2012, 27, 304-310.	1.3	67
31	Assessing The Impact Of State Policies For Prescription Drug Monitoring Programs On High-Risk Opioid Prescriptions. Health Affairs, 2018, 37, 1596-1604.	2.5	67
32	Cost-effectiveness Implications of the Timing of Antiretroviral Therapy in HIV-Infected Adults. Archives of Internal Medicine, 2002, 162, 2478.	4.3	65
33	Cost-Effectiveness of One-Time Hepatitis C Screening Strategies Among Adolescents and Young Adults in Primary Care Settings. Clinical Infectious Diseases, 2018, 66, 376-384.	2.9	62
34	Cost-Effectiveness of Rapid Syphilis Screening in Prenatal HIV Testing Programs in Haiti. PLoS Medicine, 2007, 4, e183.	3.9	58
35	Racial Differences in Virologic Failure Associated With Adherence and Quality of Life on Efavirenz-Containing Regimens for Initial HIV Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 46, 547-554.	0.9	58
36	Cost-Effectiveness of Tenofovir as First-Line Antiretroviral Therapy in India. Clinical Infectious Diseases, 2010, 50, 416-425.	2.9	54

#	ARTICLE	IF	CITATIONS
37	Cost-effective Screening for Acute Hepatitis C Virus Infection in HIV-Infected Men Who Have Sex With Men. <i>Clinical Infectious Diseases</i> , 2012, 55, 279-290.	2.9	54
38	Collaborative Depression Care Management and Disparities in Depression Treatment and Outcomes. <i>Archives of General Psychiatry</i> , 2011, 68, 627.	13.8	52
39	Cost-effectiveness of pre-exposure prophylaxis for HIV. <i>Current Opinion in HIV and AIDS</i> , 2012, 7, 587-592.	1.5	51
40	Quality of life as an outcome of opioid use disorder treatment: A systematic review. <i>Journal of Substance Abuse Treatment</i> , 2017, 76, 88-93.	1.5	50
41	Cost-Effectiveness of Buprenorphine+Naloxone Versus Extended-Release Naltrexone to Prevent Opioid Relapse. <i>Annals of Internal Medicine</i> , 2019, 170, 90.	2.0	50
42	The HEALing (Helping to End Addiction Long-term SM) Communities Study: Protocol for a cluster randomized trial at the community level to reduce opioid overdose deaths through implementation of an integrated set of evidence-based practices. <i>Drug and Alcohol Dependence</i> , 2020, 217, 108335.	1.6	50
43	Cost-Effectiveness of Earlier Initiation of Antiretroviral Therapy for Uninsured HIV-Infected Adults. <i>American Journal of Public Health</i> , 2001, 91, 1456-1463.	1.5	46
44	Cost-Effectiveness of an Intervention to Improve Adherence to Antiretroviral Therapy in HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 43, S113-S118.	0.9	46
45	The Use of an Educational Video During Informed Consent in an HIV Clinical Trial in Haiti. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 42, 588-591.	0.9	44
46	Ending the HIV epidemic in the USA: an economic modelling study in six cities. <i>Lancet HIV</i> , 2020, 7, e491-e503.	2.1	44
47	The Clinical Role and Cost-Effectiveness of Long-Acting Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2015, 60, 1102-1110.	2.9	41
48	Racial Differences in Response to Antiretroviral Therapy for HIV Infection: An AIDS Clinical Trials Group (ACTG) Study Analysis. <i>Clinical Infectious Diseases</i> , 2013, 57, 1607-1617.	2.9	40
49	Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs. <i>Addiction</i> , 2015, 110, 129-143.	1.7	39
50	Projected Estimates of Opioid Mortality After Community-Level Interventions. <i>JAMA Network Open</i> , 2021, 4, e2037259.	2.8	37
51	A Cost-Benefit Analysis of External Hip Protectors in the Nursing Home Setting. <i>Journal of the American Geriatrics Society</i> , 2005, 53, 190-197.	1.3	36
52	Cost-effectiveness of blood donor screening for <i>Babesia microti</i> in endemic regions of the United States. <i>Transfusion</i> , 2014, 54, 889-899.	0.8	36
53	Monetary conversion factors for economic evaluations of substance use disorders. <i>Journal of Substance Abuse Treatment</i> , 2017, 81, 25-34.	1.5	36
54	The impact of localized implementation: determining the cost-effectiveness of HIV prevention and care interventions across six United States cities. <i>Aids</i> , 2020, 34, 447-458.	1.0	36

#	ARTICLE	IF	CITATIONS
55	An international perspective on using opioid substitution treatment to improve hepatitis C prevention and care for people who inject drugs: Structural barriers and public health potential. <i>International Journal of Drug Policy</i> , 2015, 26, 1056-1063.	1.6	33
56	Quality-of-Life Tradeoffs for Hepatitis C Treatment: Do Patients and Providers Agree?. <i>Medical Decision Making</i> , 2008, 28, 233-242.	1.2	32
57	The cost-effectiveness of rapid HIV testing in substance abuse treatment: Results of a randomized trial. <i>Drug and Alcohol Dependence</i> , 2013, 128, 90-97.	1.6	32
58	Prescribing decisions at buprenorphine treatment initiation: Do they matter for treatment discontinuation and adverse opioid-related events?. <i>Journal of Substance Abuse Treatment</i> , 2019, 105, 37-43.	1.5	31
59	Developing a dynamic HIV transmission model for 6 U.S. cities: An evidence synthesis. <i>PLoS ONE</i> , 2019, 14, e0217559.	1.1	31
60	Clinical Impact and Cost of Monitoring for Asymptomatic Laboratory Abnormalities among Patients Receiving Antiretroviral Therapy in a Resource-Poor Setting. <i>Clinical Infectious Diseases</i> , 2010, 51, 600-608.	2.9	30
61	The Potential Epidemiological Impact of Coronavirus Disease 2019 (COVID-19) on the Human Immunodeficiency Virus (HIV) Epidemic and the Cost-effectiveness of Linked, Opt-out HIV Testing: A Modeling Study in 6 US Cities. <i>Clinical Infectious Diseases</i> , 2021, 72, e828-e834.	2.9	30
62	Can Hip Protector Use Cost-Effectively Prevent Fractures in Community-Dwelling Geriatric Populations?. <i>Journal of the American Geriatrics Society</i> , 2006, 54, 1658-1665.	1.3	29
63	Measuring benefits of opioid misuse treatment for economic evaluation: health-related quality of life of opioid-dependent individuals and their spouses as assessed by a sample of the US population. <i>Addiction</i> , 2016, 111, 675-684.	1.7	29
64	Cost-Effectiveness of Early Versus Standard Antiretroviral Therapy in HIV-Infected Adults in Haiti. <i>PLoS Medicine</i> , 2011, 8, e1001095.	3.9	29
65	Potential Risks and Benefits of HIV Treatment Simplification: A Simulation Model of a Proposed Clinical Trial. <i>Clinical Infectious Diseases</i> , 2007, 45, 1062-1070.	2.9	28
66	Study protocol for a pragmatic trial of the Consult for Addiction Treatment and Care in Hospitals (CATCH) model for engaging patients in opioid use disorder treatment. <i>Addiction Science &amp; Clinical Practice</i> , 2019, 14, 5.	1.2	28
67	What Does US Health Reform Mean for HIV Clinical Care?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 60, 72-76.	0.9	27
68	How Often Do Sensitivity Analyses for Economic Parameters Change Cost-Utility Analysis Conclusions?. <i>Pharmacoeconomics</i> , 2004, 22, 293-300.	1.7	25
69	The cost of antiretroviral therapy in Haiti. <i>Cost Effectiveness and Resource Allocation</i> , 2008, 6, 3.	0.6	25
70	Will converting naloxone to over-the-counter status increase pharmacy sales?. <i>Health Services Research</i> , 2019, 54, 764-772.	1.0	25
71	Development and Calibration of a Dynamic HIV Transmission Model for 6 US Cities. <i>Medical Decision Making</i> , 2020, 40, 3-16.	1.2	25
72	Ending the Epidemic Will Not Happen Without Addressing Racial/Ethnic Disparities in the United States Human Immunodeficiency Virus Epidemic. <i>Clinical Infectious Diseases</i> , 2020, 71, 2968-2971.	2.9	25

#	ARTICLE	IF	CITATIONS
73	Expanded HIV Screening in the United States: What Will It Cost Government Discretionary and Entitlement Programs? A Budget Impact Analysis. <i>Value in Health</i> , 2010, 13, 893-902.	0.1	23
74	Rationale, design, and methodology of a trial evaluating three models of care for HCV treatment among injection drug users on opioid agonist therapy. <i>BMC Infectious Diseases</i> , 2018, 18, 74.	1.3	23
75	Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioids. <i>International Journal of Drug Policy</i> , 2019, 72, 160-168.	1.6	23
76	Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression. <i>Aids</i> , 2007, 21, 813-823.	1.0	22
77	Offers of Hepatitis C Care Do Not Lead to Treatment. <i>Journal of Urban Health</i> , 2007, 84, 455-458.	1.8	22
78	Updating the HIV-Testing Guidelines – A Modest Change with Major Consequences. <i>New England Journal of Medicine</i> , 2013, 368, 884-886.	13.9	22
79	Cost-effectiveness of hepatitis C screening and treatment linkage intervention in US methadone maintenance treatment programs. <i>Drug and Alcohol Dependence</i> , 2018, 185, 411-420.	1.6	22
80	State Medicaid Hepatitis C Treatment Eligibility Criteria and Use of Direct-Acting Antivirals. <i>Clinical Infectious Diseases</i> , 2018, 66, 1618-1620.	2.9	22
81	Availability of HIV and HCV On-Site Testing and Treatment at Syringe Service Programs in the United States. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, e76-e78.	0.9	21
82	A Harm Reduction Approach to Treating Opioid Use Disorder in an Independent Primary Care Practice: a Qualitative Study. <i>Journal of General Internal Medicine</i> , 2021, 36, 1898-1905.	1.3	21
83	Results From a New York City Emergency Department Rapid HIV Testing Program. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 53, 420-422.	0.9	20
84	The Cost of Implementing Rapid HIV Testing in Sexually Transmitted Disease Clinics in the United States. <i>Sexually Transmitted Diseases</i> , 2014, 41, 545-550.	0.8	20
85	The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfecting patients. <i>Aids</i> , 2014, 28, 365-376.	1.0	20
86	Ending the Epidemic in America Will Not Happen if the Status Quo Continues: Modeled Projections for Human Immunodeficiency Virus Incidence in 6 US Cities. <i>Clinical Infectious Diseases</i> , 2019, 69, 2195-2198.	2.9	20
87	Harm reduction and health services provided by syringe services programs in 2019 and subsequent impact of COVID-19 on services in 2020. <i>Drug and Alcohol Dependence</i> , 2022, 232, 109323.	1.6	20
88	The cost-effectiveness of elective Cesarean delivery to prevent hepatitis C transmission in HIV-coinfecting women. <i>Aids</i> , 2004, 18, 1827-1834.	1.0	19
89	Buprenorphine and HIV Primary Care: Report of a Forum for Collaborative HIV Research Workshop. <i>Clinical Infectious Diseases</i> , 2006, 43, S254-S257.	2.9	19
90	Cost-effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practice. <i>Pharmacogenomics</i> , 2015, 16, 2007-2018.	0.6	19

#	ARTICLE	IF	CITATIONS
91	Costs of Expanded Rapid HIV Testing in Four Emergency Departments. <i>Public Health Reports</i> , 2016, 131, 71-81.	1.3	19
92	The Impact of Opioid Epidemic Trends on Hospitalised Inflammatory Bowel Disease Patients. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1030-1035.	0.6	19
93	COVID-19 Could Change the Way We Respond to the Opioid Crisisâ€”for the Better. <i>Psychiatric Services</i> , 2020, 71, 1214-1215.	1.1	19
94	Variations in Self-Rated Health Among Patients with HIV Infection. <i>Quality of Life Research</i> , 2006, 15, 503-514.	1.5	18
95	Feasibility of using audio computer-assisted self-interview (ACASI) screening in routine HIV care. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2009, 21, 992-999.	0.6	18
96	The Cost of Integrated HIV Care and Buprenorphine/Naloxone Treatment: Results of a Cross-Site Evaluation. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 56, S76-S82.	0.9	18
97	Substance use and STI acquisition: Secondary analysis from the AWARE study. <i>Drug and Alcohol Dependence</i> , 2016, 169, 171-179.	1.6	18
98	First Opioid Prescription and Subsequent High-Risk Opioid Use: a National Study of Privately Insured and Medicare Advantage Adults. <i>Journal of General Internal Medicine</i> , 2018, 33, 2156-2162.	1.3	18
99	Early Antiretroviral Therapy for Patients With Acute AIDS-Related Opportunistic Infections: A Cost-Effectiveness Analysis of ACTG A5164. <i>HIV Clinical Trials</i> , 2010, 11, 248-259.	2.0	17
100	Estimated impact of supervised injection facilities on overdose fatalities and healthcare costs in New York City. <i>Journal of Substance Abuse Treatment</i> , 2019, 106, 79-88.	1.5	17
101	Economic Evaluations of Pharmacologic Treatment for Opioid Use Disorder: A Systematic Literature Review. <i>Value in Health</i> , 2021, 24, 1068-1083.	0.1	17
102	Comparison of Rates of Overdose and Hospitalization After Initiation of Medication for Opioid Use Disorder in the Inpatient vs Outpatient Setting. <i>JAMA Network Open</i> , 2020, 3, e2029676.	2.8	17
103	The cost of HIV medication adherence support interventions: Results of a cross-site evaluation. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2005, 17, 927-937.	0.6	16
104	Sexually Active HIV-Positive Patients Frequently Report Never Using Condoms in Audio Computer-Assisted Self-Interviews Conducted at Routine Clinical Visits. <i>AIDS Patient Care and STDs</i> , 2008, 22, 123-129.	1.1	16
105	Achieving Effective Antidepressant Pharmacotherapy in Primary Care: The Role of Depression Care Management in Treating Late-Life Depression. <i>Journal of the American Geriatrics Society</i> , 2009, 57, 895-900.	1.3	16
106	A synthesis of cost-utility analysis literature in infectious disease. <i>Lancet Infectious Diseases</i> , The, 2005, 5, 383-391.	4.6	15
107	Efavirenz-Based Regimens in Treatment-Naive Patients with a Range of Pretreatment HIV-1 RNA Levels and CD4 Cell Counts. <i>Journal of Infectious Diseases</i> , 2008, 197, 1006-1010.	1.9	15
108	Impact of Illicit Drug Use on Health-Related Quality of Life in Opioid-Dependent Patients Undergoing HIV Treatment. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 70, 304-310.	0.9	15

#	ARTICLE	IF	CITATIONS
109	Strategies for Improving Hepatitis C Treatment Access in the United States: State Officials Address High Drug Prices, Stigma, and Building Treatment Capacity. <i>Journal of Public Health Management and Practice</i> , 2019, 25, 245-252.	0.7	15
110	Joint Utility Estimators in Substance Use Disorders. <i>Value in Health</i> , 2017, 20, 458-465.	0.1	14
111	Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofw266.	0.4	14
112	Health-Related Quality of Life in HIV-Infected and At-Risk Women. <i>Medical Decision Making</i> , 2014, 34, 800-808.	1.2	13
113	Cost-effectiveness of Hepatitis C Virus Treatment Models for People Who Inject Drugs in Opioid Agonist Treatment Programs. <i>Clinical Infectious Diseases</i> , 2020, 70, 1397-1405.	2.9	13
114	Targeting community-based naloxone distribution using opioid overdose death rates: A descriptive analysis of naloxone rescue kits and opioid overdose deaths in Massachusetts and Rhode Island. <i>International Journal of Drug Policy</i> , 2021, 98, 103435.	1.6	13
115	Design Issues in Initial HIV-Treatment Trials: Focus on Actg A5095. <i>Antiviral Therapy</i> , 2006, 11, 751-760.	0.6	13
116	AIDS Drug Assistance Programs: Managers Confront Uncertainty And Need To Adapt As The Affordable Care Act Kicks In. <i>Health Affairs</i> , 2013, 32, 1063-1071.	2.5	12
117	Carotid Artery Stenosis: Cost-effectiveness of Assessment of Cerebrovascular Reserve to Guide Treatment of Asymptomatic Patients. <i>Radiology</i> , 2015, 274, 455-463.	3.6	12
118	On-site bundled rapid HIV/HCV testing in substance use disorder treatment programs: study protocol for a hybrid design randomized controlled trial. <i>Trials</i> , 2016, 17, 117.	0.7	12
119	Cost-Effectiveness Analysis of <i>Ugt1A1</i> Genetic Testing to Inform Antiretroviral Prescribing in HIV Disease. <i>Antiviral Therapy</i> , 2013, 18, 399-408.	0.6	11
120	Health-related quality of life and opioid use disorder pharmacotherapy: A secondary analysis of a clinical trial. <i>Drug and Alcohol Dependence</i> , 2020, 215, 108221.	1.6	11
121	Modeling the Cost Effectiveness of Neuroimaging-Based Treatment of Acute Wake-Up Stroke. <i>PLoS ONE</i> , 2016, 11, e0148106.	1.1	11
122	Treating and Preventing HIV with Generic Drugs – Barriers in the United States. <i>New England Journal of Medicine</i> , 2018, 378, 316-319.	13.9	10
123	Hepatitis C Virus Incidence in a Cohort in Medication-Assisted Treatment for Opioid Use Disorder in New York City. <i>Journal of Infectious Diseases</i> , 2020, 222, S322-S334.	1.9	10
124	An In-Depth Survey of the Screening and Assessment Practices of Highly Regarded Adolescent Substance Abuse Treatment Programs. <i>Journal of Child and Adolescent Substance Abuse</i> , 2009, 19, 33-47.	0.5	9
125	Lives Saved by Expanding HIV Treatment Availability in Resource-Limited Settings. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, e40-e48.	0.9	9
126	Telementoring of primary care providers delivering hepatitis C treatment in New York: Results from Project INSPIRE. <i>Learning Health Systems</i> , 2018, 2, e10056.	1.1	9



#	ARTICLE	IF	CITATIONS
127	Spatial distribution and characteristics of HIV clusters in Ethiopia. <i>Tropical Medicine and International Health</i> , 2020, 25, 301-307.	1.0	9
128	Bundling Rapid Human Immunodeficiency Virus and Hepatitis C Virus Testing to Increase Receipt of Test Results. <i>Medical Care</i> , 2020, 58, 445-452.	1.1	9
129	Improving health equity and ending the HIV epidemic in the USA: a distributional cost-effectiveness analysis in six cities. <i>Lancet HIV</i> , 2021, 8, e581-e590.	2.1	9
130	Cost of pharmacotherapy for opioid use disorders following inpatient detoxification. <i>American Journal of Managed Care</i> , 2018, 24, 526-531.	0.8	9
131	Cost-effectiveness of Adding an Agent That Improves Immune Responses to Initial Antiretroviral Therapy (ART) in HIV-Infected Patients: Guidance for Drug Development. <i>HIV Clinical Trials</i> , 2012, 13, 1-10.	2.0	8
132	Cost-Effectiveness of Meningococcal Vaccination Among Men Who Have Sex With Men in New York City. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 146-154.	0.9	8
133	State Policies for Prescription Drug Monitoring Programs and Adverse Opioid-related Hospital Events. <i>Medical Care</i> , 2020, 58, 610-616.	1.1	8
134	Health economic design for cost, cost-effectiveness and simulation analyses in the HEALing Communities Study. <i>Drug and Alcohol Dependence</i> , 2020, 217, 108336.	1.6	8
135	Hepatitis C Virus (HCV) Care Continuum Outcomes and HCV Community Viral Loads Among Patients in an Opioid Treatment Program. <i>Journal of Infectious Diseases</i> , 2020, 222, S335-S345.	1.9	8
136	Community-based naloxone coverage equity for the prevention of opioid overdose fatalities in racial/ethnic minority communities in Massachusetts and Rhode Island. <i>Addiction</i> , 2022, 117, 1372-1381.	1.7	8
137	Does higher cost mean better quality? evidence from highly-regarded adolescent drug treatment programs. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2007, 2, 23.	1.0	7
138	Structural Design and Data Requirements for Simulation Modelling in HIV/AIDS: A Narrative Review. <i>Pharmacoeconomics</i> , 2019, 37, 1219-1239.	1.7	7
139	A Cost Reimbursement Model for Hepatitis C Treatment Care Coordination. <i>Journal of Public Health Management and Practice</i> , 2019, 25, 253-261.	0.7	7
140	Economic evaluation in the National Drug Abuse Treatment Clinical Trials Network: Past, present, and future. <i>Journal of Substance Abuse Treatment</i> , 2020, 112, 18-27.	1.5	7
141	Addressing Barriers to On-site HIV and HCV Testing Services in Methadone Maintenance Treatment Programs in the United States: Findings From a National Multisite Qualitative Study. <i>Journal of Public Health Management and Practice</i> , 2021, 27, 393-402.	0.7	7
142	Improving HIV service delivery for people who inject drugs in Kazakhstan: study protocol for the Bridge stepped-wedge trial. <i>Implementation Science</i> , 2019, 14, 62.	2.5	6
143	Why Maximizing Quality-Adjusted Life Years, rather than Reducing HIV Incidence, Must Remain Our Objective in Addressing the HIV/AIDS Epidemic. <i>Journal of the International Association of Providers of AIDS Care</i> , 2019, 18, 232595821882196.	0.6	6
144	Cost-effectiveness of a Medical Care Coordination Program for People With HIV in Los Angeles County. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz537.	0.4	6

#	ARTICLE	IF	CITATIONS
145	Community viral load and hepatitis C virus infection: Community viral load measures to aid public health treatment efforts and program evaluation. <i>Journal of Clinical Virology</i> , 2020, 124, 104285.	1.6	6
146	NIDA's Clinical Trials Network: An Opportunity for HIV Research in Community Substance Abuse Treatment Programs. <i>American Journal of Drug and Alcohol Abuse</i> , 2011, 37, 283-293.	1.1	5
147	Cost-Effectiveness of Generic Antiretroviral Therapy. <i>Annals of Internal Medicine</i> , 2013, 158, 776.	2.0	5
148	When "the Cure" Is the Risk: Understanding How Substance Use Affects HIV and HCV in a Layered Risk Environment in San Juan, Puerto Rico. <i>Health Education and Behavior</i> , 2017, 44, 748-757.	1.3	5
149	Criminal justice measures for economic data harmonization in substance use disorder research. <i>Health and Justice</i> , 2018, 6, 17.	0.9	5
150	Impact of Removing Medicaid Fee-for-Service Hepatitis C Virus (HCV) Treatment Restrictions on HCV Provider Experience with Medicaid Managed Care Organizations in New York City. <i>Journal of Urban Health</i> , 2021, 98, 563-569.	1.8	5
151	How simulation modeling can support the public health response to the opioid crisis in North America: Setting priorities and assessing value. <i>International Journal of Drug Policy</i> , 2021, 88, 102726.	1.6	5
152	Robust Prescription Monitoring Programs and Abrupt Discontinuation of Long-term Opioid Use. <i>American Journal of Preventive Medicine</i> , 2021, 61, 537-544.	1.6	5
153	Costs of Opioid Overdose Education and Naloxone Distribution in New York City. <i>Substance Abuse</i> , 2022, 43, 692-698.	1.1	5
154	Inappropriate Medication in Home Health Care. <i>Journal of General Internal Medicine</i> , 2012, 27, 491-491.	1.3	4
155	Prioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the US. <i>HIV Clinical Trials</i> , 2015, 16, 207-218.	2.0	4
156	Performance of a Mathematical Model to Forecast Lives Saved from HIV Treatment Expansion in Resource-Limited Settings. <i>Medical Decision Making</i> , 2015, 35, 230-242.	1.2	4
157	Implementation of a Nationwide Health Economic Consultation Service to Assist Substance use Researchers: Lessons Learned. <i>Substance Abuse</i> , 2018, 39, 185-189.	1.1	4
158	Dissemination Science to Advance the Use of Simulation Modeling: Our Obligation Moving Forward. <i>Medical Decision Making</i> , 2020, 40, 718-721.	1.2	4
159	Ending the HIV Epidemic Among Persons Who Inject Drugs: A Cost-Effectiveness Analysis in Six US Cities. <i>Journal of Infectious Diseases</i> , 2020, 222, S301-S311.	1.9	4
160	Can the "Ending the HIV Epidemic" initiative transition the USA towards HIV/AIDS epidemic control?. <i>Aids</i> , 2020, 34, 2325-2328.	1.0	4
161	Cost-effectiveness of Adding an Agent That Improves Immune Responses to Initial Antiretroviral Therapy (ART) in HIV-Infected Patients: Guidance for Drug Development. <i>HIV Clinical Trials</i> , 2012, 13, 1-10.	2.0	4
162	The State(s) of Health: Federalism and the Implementation of Health Reform in the Context of HIV Care. <i>Public Administration Review</i> , 2013, 73, S94.	2.9	3

#	ARTICLE	IF	CITATIONS
163	The structural and health policy environment for delivering integrated HIV and substance use disorder treatments in Puerto Rico. <i>BMC Health Services Research</i> , 2017, 17, 232.	0.9	3
164	No change in health-related quality of life for at-risk U.S. women and men starting HIV pre-exposure prophylaxis (PrEP): Findings from HPTN 069/ACTG A5305. <i>PLoS ONE</i> , 2018, 13, e0206577.	1.1	3
165	Hepatitis C Treatment Uptake by New Prescribers After the Introduction of Direct Acting Antivirals. <i>Journal of General Internal Medicine</i> , 2020, 35, 975-977.	1.3	3
166	Budget impact of Medicaid Section 1115 demonstrations for early HIV treatment. <i>Health Care Financing Review</i> , 2005, 26, 67-80.	1.8	3
167	The Value of HIV Screening in the United States in the Era of Effective Treatment. <i>Medical Decision Making</i> , 2013, 33, 457-459.	1.2	2
168	Cost of an HIV Medical Care Coordination Program in Los Angeles County. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, e15-e17.	0.9	2
169	Evaluation of Alcohol Taxes as a Public Health Opportunity to Reduce Liver Transplant Listings for Alcohol-Related Liver Disease. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 2307-2315.	1.4	2
170	Considerations for Developing Applied Health Policy Models: The Example of HIV Treatment Expansion in Resource-Limited Settings. <i>Profiles in Operations Research</i> , 2013, , 313-339.	0.3	2
171	Human Immunodeficiency Virus transmission by HIV risk group and along the HIV care continuum. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, Publish Ahead of Print, .	0.9	2
172	Can urban methadone patients complete health utility assessments?. <i>Patient Education and Counseling</i> , 2008, 71, 302-307.	1.0	1
173	2216. Hepatitis C Treatment Wanted Yet Not Received: Barriers to Receiving HCV Treatment Among People Who Inject Drugs. <i>Open Forum Infectious Diseases</i> , 2018, 5, S654-S655.	0.4	1
174	The Value and Challenge of Frequent Human Immunodeficiency Virus (HIV) Testing Among Young Men Who Have Sex With Men in the United States. <i>Clinical Infectious Diseases</i> , 2020, 73, e1936-e1937.	2.9	1
175	Harmonizing healthcare and other resource measures for evaluating economic costs in substance use disorder research. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2021, 16, 32.	1.0	1
176	Cost-effectiveness implications of increasing the efficiency of the extended-release naltrexone induction process for the treatment of opioid use disorder: a secondary analysis. <i>Addiction</i> , 2021, 116, 3444-3453.	1.7	1
177	Hepatitis C Treatment by Nonspecialist Providers in the Direct-acting Antiviral Era. <i>Medical Care</i> , 2021, 59, 795-800.	1.1	1
178	Cost of Hepatitis C care facilitation for HIV/Hepatitis C Co-infected people who use drugs. <i>Drug and Alcohol Dependence</i> , 2022, 232, 109265.	1.6	1
179	Letter to the Editor. <i>Medical Decision Making</i> , 2003, 23, 542-543.	1.2	0
180	RESPONSE TO COMMENTARY BY DR. OLIVER AND COLLEAGUES ON HIP PROTECTORS. <i>Journal of the American Geriatrics Society</i> , 2006, 54, 1159-1160.	1.3	0

#	ARTICLE	IF	CITATIONS
181	Preventing Vertical Hepatitis C Virus Transmission. <i>Clinical Infectious Diseases</i> , 2007, 45, 802-802.	2.9	0
182	RESPONSE LETTER TO DR. DRINKA. <i>Journal of the American Geriatrics Society</i> , 2007, 55, 960-960.	1.3	0
183	862. Spatial Distribution of HIV Transmission in Ethiopia and Characteristics of HIV Clusters. <i>Open Forum Infectious Diseases</i> , 2018, 5, S21-S21.	0.4	0
184	Commentary on Barbosa et al. (2019): The value of using community simulation modeling to achieve HCV elimination targets in people who inject drugs. <i>Addiction</i> , 2019, 114, 2279-2280.	1.7	0
185	The Experience of Implementing a Low-Threshold Buprenorphine Treatment Program in a Non-Urban Medical Practice. <i>Substance Use and Misuse</i> , 2022, 57, 308-315.	0.7	0